SecBot SecBot
DEFA14A ·Filed Apr 17, 2026

RLMD

RELMADA THERAPEUTICS, INC.
NEUTRAL
Impact 3/10
Horizonimmediate Processed7mo ago SEC0001213900-26-045194
Proxy solicitation materials
Actionable Insight • Neutral

Investors should consider voting on the proposals, particularly the equity plan expansion and share authorization increase which could lead to future dilution. Monitor for any insider trading activity around these governance changes.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.37
T+0 close · Apr 17, 2026 · via day close
Latest settled
−15.74%
T+60 · $6.21
Vs SPY
−22.52%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 20 $7.37entry
  2. T+1 · 7mo ago −3.12%α −2.47% · $7.14
  3. T+5 · 7mo ago −4.61%α −5.53% · $7.03
  4. T+20 · 6mo ago −13.98%α −18.18% · $6.34
  5. T+60 · 4mo ago −15.74%α −22.52% · $6.21
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Relmada Therapeutics is holding its 2026 annual meeting where shareholders will vote on four key proposals: electing two Class II directors, ratifying the appointment of CBIZ CPAs P.C. as auditors, increasing the number of shares available under its equity incentive plan by 3 million, and increasing its authorized common stock from 150 million to 200 million shares. The filing is a routine proxy statement with no material financial data disclosed.

Key Financial Metrics

Vote
director election
Meeting
2026-05-27
Seats Contested
2

Key Facts

  • Relmada Therapeutics is holding its 2026 annual meeting
  • Shareholders will vote to elect two Class II directors: Charles J. Casamento and Sergio Traversa
  • Proposal to ratify CBIZ CPAs P.C. as independent auditors for 2026
  • Proposal to increase shares available under the 2021 Equity Incentive Plan by 3 million
  • Proposal to increase authorized common stock from 150 million to 200 million shares

Financial Impact

3 million additional shares for equity incentives, increase in authorized shares from 150M to 200M

dilutionequity

Risk Factors

  • Potential dilution from increased share authorization and equity incentives
  • Governance risks if shareholder approval is not obtained for key proposals

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001213900-26-045194
Document: 0001213900-26-045194-index-headers.html0001213900-26-045194
Document: 0001213900-26-045194-index.html0001213900-26-045194
Document: 0001213900-26-045194.txt0001213900-26-045194

Track record

11 reports on RLMD

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +38.81% at T+60 after the May 13, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $3.54 Now $3.61 −1.98% settles Dec 15
  2. Nov 16, 2026today 8-K Neutral 3/10 Entry $4.16 Now $3.61 −13.23% settles Dec 15
  3. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $4.21 Now $3.61 −14.25% settles Dec 14
  4. Sep 11, 20269w ago Insider Cluster Bullish 6/10 Entry $4.52 to $3.39 Now $3.61 −20.13% ▼ −25.00% −26.87% vs SPY
  5. May 13, 202626w ago S-3ASR Bearish 6/10 Entry $7.42 to $6.65 Now $3.61 +51.35% ▲ +10.38% +9.52% vs SPY
  6. May 12, 202626w ago 8-K Neutral 4/10 Entry $7.49 to $6.52 Now $3.61 −51.80% ▼ −12.95% −12.34% vs SPY
  7. Apr 17, 202630w ago DEFA14A Neutral 3/10 Viewing Entry $7.37 to $6.34 Now $3.61 −51.02% ▼ −13.98% −18.18% vs SPY
  8. Apr 3, 202632w ago S-3 Neutral 3/10 Entry $6.90 to $7.41 Now $3.61 −47.68% ▲ +7.39% −1.59% vs SPY
  9. Mar 19, 202634w ago Press Release Bullish 8/10 Entry $6.07 to $7.37 Now $3.61 −40.53% ▲ +21.42% +12.10% vs SPY
  10. Mar 12, 202635w ago Press Release Neutral 3/10 Entry $6.15 to $7.29 Now $3.61 −41.30% ▲ +18.54% +16.56% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 17, 2026